Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification

Coronary Artery Calcification Clinical Trial

Official title:

Association Between NAFLD and Coronary Artery Calcification

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01158066
• Other study ID #: NAFLD and CAC
• Status: Not yet recruiting
• Phase: N/A
• First received: July 4, 2010
• Last updated: April 5, 2011
• Start date: August 2011
• Est. completion date: March 2012

Study information

• Verified date: June 2010
• Source: Ziv Hospital
• Contact: Assy Nimer, MD
• Phone: +97246828445
• Email: assy.n[@]ziv.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial

Description:

Coronary artery disease are 8 times more prevalent in patients with NAFLD that the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial. AIM: the aim is to evaluate the association between CAC score ( CT) and NAFLD (CT). the working hypothesis is that Beside the traditional risk factors including age, diabetes, NAFLD is also associated with moderate to high risk of CAD.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: March 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients who will undergo cardiac CT for patients with low to intermediate risk for CAD

Exclusion Criteria:

• Patients with PCI or CABG will be excluded

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Arteriosclerosis
• Calcinosis
• Coronary Artery Calcification
• Coronary Artery Disease

Intervention

Procedure:
• CT Cardiac
the patient will undergo cardiac CT

Locations

Country	Name	City	State
Israel	Ziv medical center liver unit	Safed, Israel

Sponsors (1)

Lead Sponsor	Collaborator
Ziv Hospital

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total calcium score measurement	total calcium score will be measured	1 month	No